| http://www.w3.org/ns/prov#value | - The method of claim 1, wherein the patient is a pediatric patient and the TNF?? inhibitor is TNFR:Fc, and further wherein the TNFR:Fc is administered by subcutaneous injection one or more times per week at a dose of 0.4 mg/kg of body weight, up to a maximum of 25 mg per dose. 6.
|
